arrow
D

Diego Signorelli

University of Florence
H指数:37
被引数:4,472

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Hyperprogression Upon Cemiplimab Alone or With Short Course Chemotherapy in PD-L1 ≥ 50% Non-small Cell Lung Cancer: A Biomarker Guided Multicenter International Phase 2 Trial-HYPERBOLIC Study

PD-L1 ≥ 50% 非小细胞肺癌中cemiplimab单药或联合短程化疗的超进展:一项生物标志物指导的多中心国际II期试验—HYPERBOLIC研究

2026-09-010
PRE
Braf-mutant metastatic non-small-cell lung cancer: Real world data from the Italian biomarker atlas database

Braf突变转移性非小细胞肺癌: 来自意大利生物标志物图谱数据库的真实世界数据

2026-01-210
OAAI
Recommendations for radiotherapy in patients with lung cancer and interstitial lung disease: A Delphi consensus process of the Italian association of radiotherapy and clinical oncology (AIRO)

关于肺癌合并间质性肺病患者放射治疗推荐:意大利放射治疗与临床肿瘤学会(AIRO)的Delphi共识过程

2025-11-030
PRE
Long-term outcomes from pembrolizumab monotherapy in patients with advanced NSCLC, PD-L1 expression ≥ 50 %, and poor performance status: Transformer-based AI to characterize prognostic complexity

长期接受帕博利珠单抗单药治疗的患者中,具有晚期非小细胞肺癌、PD-L1表达≥50%且体力状况较差者的长期结局:基于Transformer的AI用于表征预后复杂性

2025-10-160
OAAI
Rationale and design of the AUSTRAL trial: An open-label, multicenter, phase II study evaluating radiotherapy followed by durvalumab (MEDI4736) and ceralasertib (AZD6738) in stage III NSCLC patients with thoracic relapses and/or oligometastases after the PACIFIC regimen.

AUSTRAL试验的原理与设计:一项开放标签、多中心、II期研究,旨在评估在完成PACIFIC方案治疗后出现胸腔内复发和/或寡转移的III期NSCLC患者中,采用放疗后序贯度鲁瓦木单抗(MEDI4736)和塞拉拉塞替(AZD6738)的治疗效果。

2025-07-120
PRE
Activity of osimeRTInib in non-small-cell lung Cancer with UNcommon epidermal growth factor receptor mutations: retrospective Observational multicenter study (ARTICUNO)

奥希替尼在具有罕见表皮生长因子受体突变的非小细胞肺癌中的活性: 回顾性观察性多中心研究 (ARTICUNO)

2024-06-011
OAAI
Association Between Lung Immune Prognostic Index and Durvalumab Consolidation Outcomes in Patients With Locally Advanced Non-Small-Cell Lung Cancer
2024-05-014
PRE
APOLLO 11 Project, Consortium in Advanced Lung Cancer Patients Treated With Innovative Therapies: Integration of Real-World Data and Translational Research
2024-03-011
OAAI
Repotrectinib Overcomes F2004V Resistance Mutation in ROS1-Rearranged NSCLC: A Case Report

Reptrectinib克服ROS1-Rearranged NSCLC的F2004V耐药突变: 病例报告

2023-11-014
OA
Exploring the Role of Immunotherapy-Based Treatments for Advanced Non-Small-Cell Lung Cancer With Novel Driver Alterations
2023-11-011
OAAI
A systematic review and meta-analysis on the optimal treatment duration of checkpoint inhibitoRS in solid tumors: The OTHERS study
2023-07-0114
OAAI
Real-world data to build explainable trustworthy artificial intelligence models for prediction of immunotherapy efficacy in NSCLC patients
2023-01-2311
OAAI
PEOPLE (NCT03447678), a first-line phase II pembrolizumab trial, in negative and low PD-L1 advanced NSCLC: clinical outcomes and association with circulating immune biomarkers

人 (NCT03447678),一线II期pembrolizumab试验,在阴性和低PD-L1晚期NSCLC中: 临床结果和与循环免疫生物标志物的关联

2022-12-015
OAAI
Comparative assessment of early mortality risk upon immune checkpoint inhibitors alone or in combination with other agents across solid malignancies: a systematic review and meta-analysis

免疫检查点抑制剂单独或联合其他药物治疗实体恶性肿瘤早期死亡风险的比较评估: 系统回顾和荟萃分析

2022-12-01126
PRE
Circulating Fatty Acid Profile as a Biomarker for Immunotherapy in Advanced Non-Small Cell Lung Cancer

循环脂肪酸谱作为晚期非小细胞肺癌免疫治疗的生物标志物

2022-11-015
PRE
Circulating CD81-expressing extracellular vesicles as biomarkers of response for immune-checkpoint inhibitors in advanced NSCLC
2022-09-2010
OAAI